<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00356915</url>
  </required_header>
  <id_info>
    <org_study_id>BT0300-302-INT</org_study_id>
    <nct_id>NCT00356915</nct_id>
  </id_info>
  <brief_title>Itraconazole Tablets Vs. Itraconazole Capsules vs. Placebo in Onychomycosis of the Toenail.</brief_title>
  <official_title>A Phase III Randomized, Evaluator-Blind, Parallel Group Study of the Safety and Efficacy of Itraconazole Tablets, Itraconazole Capsules and Placebo in the Treatment of Onychomycosis of the Toenail.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stiefel, a GSK Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Onychomycosis is a common condition accounting for approximately half of all nail disorders.
      It is most commonly caused by dermatophytes. Itraconazole has been approved for the treatment
      of onychomycosis in the United States with an approved dosage regimen for the treatment of
      onychomycosis of the toenail of once daily (QD) treatment with 200mg of itraconazole (two 100
      mg capsules) for 12 weeks. Barrier Therapeutics has developed a 200 mg tablet which could be
      used in a more convenient one-tablet-per-day dosing regimen. This clinical trial will compare
      the efficacy and safety of this new tablet formulation with itraconazole capsules and
      placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Onychomycosis is common and accounts for about half of all nail disorders. Usually the cause
      is due to dermatophytes, either Trichophyton rubrum (71%) or Trichophyton mentagrophytes
      (20%) but may also be due to yeast infection, usually Candida albicans.

      The prevalence of onychomycosis in the United States population as a whole is 13% and is more
      prevalent in the elderly (60%). Onychomycosis of the toenail recurs and is thought to have a
      genetic component.

      Onychomycosis can result in permanent nail deformity. This disease has a significant impact
      on the patient's quality of life (e.g., concern with the appearance of the toenails and
      fingernails, interference with wearing shoes, walking and sports activities).

      Itraconazole has been approved for the treatment of onychomycosis in the United States since
      the mid-nineteen-nineties. The approved dosage regimen for treatment of onychomycosis of the
      toenail is once daily (QD) treatment with 200 mg of itraconazole (Sporanox®, Janssen
      Pharmaceutical Products, L.P., Titusville, NJ, USA) for 12 weeks. The approved dosage form is
      a 100mg capsule. Barrier Therapeutics has developed a 200mg tablet which could be used in a
      more convenient one-tablet-per-day dosing regimen.

      This clinical trial will compare the efficacy and safety of this new tablet formulation with
      itraconazole capsules and placebo.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2006</start_date>
  <completion_date type="Actual">October 2008</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical and Mycological Cure of Target Toenail</measure>
    <time_frame>1 year</time_frame>
    <description>This study was designed to evaluate the superiority of itraconazole tablets to placebo tablets.
Clinical Cure was defined as an IGA score of 0 for the target toenail; Mycological Cure was defined as a negative potassium hydroxide (KOH) exam and a negative culture for dermatophytes of the target toenail.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Complete Cure - Itraconazole Tablets Compared to Itraconazole Capsules</measure>
    <time_frame>12 months</time_frame>
    <description>The primary efficacy endpoint was Compete Cure (consisting of a Clinical Cure and a Mycological Cure) at week 52. In this study, Clinical Cure was defined as an Investigator's Global Assessment (IGA) score of 0 for the target toenail; Mycological Cure was defined as a negative potassium hydroxide (KOH) examination and a negative culture outcome for dermatophytes of the target toenail. The efficacy analyses were conducted to demonstrate the non-inferiority of 1 itraconazole 200-mg tablet to 2 itraconazole 100-mg capsule.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Improvement of the Target Toenail</measure>
    <time_frame>12 months</time_frame>
    <description>Clinical Improvement consisted of a mycological cure and an Investigator's Global Assessment (IGA) score less than or equal to 1 at week 52.
The Investigator's Global Assessment (IGA) assesses the overall severity of onychomycosis on the target toenail and takes into consideration, onycholysis, hyperkeratosis and percent nail involvement.
0 = Clinical Cure: No evidence of onychomycosis.
1 = Clinical Improvement: Minimal evidence of onychomycosis. 2 = Mild: ≤25% dystrophy and/or onycholysis. 3 = Moderate: ≤50% dystrophy with onycholysis. 4 = Severe: &gt;50% dystrophy with onycholysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Improvement Compared to Placebo</measure>
    <time_frame>12 months</time_frame>
    <description>Clinical Improvement consisted of a mycological cure and an Investigator's Global Assessment (IGA) score less than or equal to 1 at week 52.
The Investigator's Global Assessment(IGA)assesses the overall severity of onychomycosis on the target toenail and takes into consideration, onycholysis, hyperkeratosis and percent nail involvement.
0 = Clinical Cure: No evidence of onychomycosis.
1 = Clinical Improvement: Minimal evidence of onychomycosis. 2 = Mild: ≤25% dystrophy and/or onycholysis. 3 = Moderate: ≤50% dystrophy with onycholysis. 4 = Severe: &gt;50% dystrophy with onycholysis.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1381</enrollment>
  <condition>Onychomycosis</condition>
  <arm_group>
    <arm_group_label>Itraconazole tablets</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Itraconazole 200 mg tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Itraconazole capsules</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Two Itraconazole 100 mg capsules were taken daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo tablets</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The itraconazole 200-mg tablets and placebo tablets exactly matched one another and were white to slightly grey in color, were oblong and biconvex in shape, and were melt-extrusion, film-coated.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Itraconazole 100mg capsules</intervention_name>
    <description>Subjects took two 100mg capsules once per day after a full meal. The dose dose was taken the day before the Week 12 visit.</description>
    <arm_group_label>Itraconazole capsules</arm_group_label>
    <other_name>Sporanox®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Itraconazole 200mg tablets</intervention_name>
    <description>Subjects took one 200mg tablet once per day after a full meal. The last dose was taken the day before the Week 12 visit.</description>
    <arm_group_label>Itraconazole tablets</arm_group_label>
    <other_name>Onmel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo tablets</intervention_name>
    <description>Placebo tablets are the same as the Itraconazole tablets but without the active drug included. Subjects took one tablet once per day after a full meal. The last tablet was taken the day before the Week 12 visit.</description>
    <arm_group_label>Placebo tablets</arm_group_label>
    <other_name>placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of onychomycosis of at least one great toenail

          -  Percent Nail Involvement Score of the more severely affected great toenail (the Target
             Toenail) must be between 2 and 3 (25-75% of the nail unit).

          -  Length of Unaffected Part of the Target Toenail ≥2mm

          -  Direct microscopic examination with KOH that is positive for the hyphae associated
             with dermatophytes on the target toenail

          -  Subjects must have signed informed consent

          -  If the subject is woman of childbearing potential, she must have a negative urine
             pregnancy test and agree to use an effective form of birth control until the first
             menses after 60 days following the last dose of study medication.

        Exclusion Criteria:

          -  Onychomycosis caused by Candida spp. without the presence of a dermatophyte

          -  Participation in a clinical trial for the systemic treatment of onychomycosis of the
             toenail within 24 weeks prior to Visit 1

          -  Use of systemic antifungals within 12 weeks prior to Visit 1

          -  Use of topical antifungal nail lacquer within 30 days prior to Visit 1

          -  Use of any other topical onychomycosis treatment on any toenail within 7 days prior to
             Visit 1

          -  Evidence of ventricular dysfunction such as congestive heart failure (CHF) or a
             history of CHF

          -  Known liver disease or a history of liver toxicity with other drugs

          -  Use of systemic immunosuppressants
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Radiant Research -Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Alabama School of Medicine</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research - Tucson</name>
      <address>
        <city>Tuscon</city>
        <state>Arizona</state>
        <zip>85710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Burke Pharmaceutical Research</name>
      <address>
        <city>Hot Springs</city>
        <state>Arkansas</state>
        <zip>71913</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East Bay Dermatology Medical Group Inc.</name>
      <address>
        <city>Fremont</city>
        <state>California</state>
        <zip>94538</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skin Surgey Medical Group</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Therapeutics Clinical Research</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143-0517</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research - Santa Rosa</name>
      <address>
        <city>Santa Rosa</city>
        <state>California</state>
        <zip>95405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meridian Skincare</name>
      <address>
        <city>Englewood</city>
        <state>Colorado</state>
        <zip>80112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Savin Center</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Stephen Horwitz</name>
      <address>
        <city>Aventure</city>
        <state>Florida</state>
        <zip>33180</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>International Dermatology Research Inc.</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FMX Research Corporation</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33175</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Dermatology and Cosmetic Surgery</name>
      <address>
        <city>Ormond Beach</city>
        <state>Florida</state>
        <zip>32174</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research - St. Petersburg</name>
      <address>
        <city>St. Petersburg</city>
        <state>Florida</state>
        <zip>33781</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research - West Palm Beach</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research - Atlanta West</name>
      <address>
        <city>Austell</city>
        <state>Georgia</state>
        <zip>30106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gwinnett Clinical Research Center Inc.</name>
      <address>
        <city>Snellville</city>
        <state>Georgia</state>
        <zip>30078</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwest Clinical Trials</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>83704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research - Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research - Kansas City</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. David Fivenson</name>
      <address>
        <city>Ann Arbour</city>
        <state>Michigan</state>
        <zip>48103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skin and Vein Center</name>
      <address>
        <city>Troy</city>
        <state>Michigan</state>
        <zip>48083</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minnesota Clinical Study Center</name>
      <address>
        <city>Fridley</city>
        <state>Minnesota</state>
        <zip>55432</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Medical Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55417</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Eduardo Tschen</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skin Specialty Group</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Consulting Services</name>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Clinical Research Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research - Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45249</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwest Cutaneous Research</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Medical Research Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97223</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rhode Island Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research - Anderson</name>
      <address>
        <city>Anderson</city>
        <state>South Carolina</state>
        <zip>29621</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research - Greenville</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29617</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. J. M. Humeniuk</name>
      <address>
        <city>Greer</city>
        <state>South Carolina</state>
        <zip>29651</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology East</name>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <zip>38138</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Associates of Knoxville</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37917</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tennessee Clinical Research Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DermResearch Inc.</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78759</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Terry Jones</name>
      <address>
        <city>Bryan</city>
        <state>Texas</state>
        <zip>77802</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research - Dallas North</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Stephen Miller</name>
      <address>
        <city>San Antoinio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endeavor Clinical Trials</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Research Center</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Valley Dermatology Center</name>
      <address>
        <city>West Jordan</city>
        <state>Utah</state>
        <zip>84088</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pariser Dermatology Specialists Ltd.</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>235507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research - Tacoma</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98499</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Madison Skin and Research Inc.</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53719</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Healthcare S. C.</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Kirk Barber</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2S3B3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Richard Thomas</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z3Y1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Marc Bourcier</name>
      <address>
        <city>Moncton</city>
        <state>New Brunswick</state>
        <zip>E1C8X3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Aditja Gupta</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N5X2P1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Chuck Lynde</name>
      <address>
        <city>Markham</city>
        <state>Ontario</state>
        <zip>L3P7N8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>EntraLogix</name>
      <address>
        <city>Oakville</city>
        <state>Ontario</state>
        <zip>L6K1E1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Jerry Tan</name>
      <address>
        <city>Windsor</city>
        <state>Ontario</state>
        <zip>N8W5L7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Robert Bissonnette</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2K4L5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Edifico Professional Guarionex Lopez</name>
      <address>
        <city>Santo Domingo</city>
        <country>Dominican Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Manuel Briones</name>
      <address>
        <city>Guayaquil</city>
        <country>Ecuador</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Orquidea Blanca</name>
      <address>
        <city>San Pedro</city>
        <state>Sula</state>
        <country>Honduras</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Metropolis II</name>
      <address>
        <city>Panama City</city>
        <country>Panama</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Langeberg Medical Centre</name>
      <address>
        <city>Cape Town</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cape Town</name>
      <address>
        <city>Cape Town</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Z. F. Ahmed Vawda</name>
      <address>
        <city>Durban</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DJW Navorsing</name>
      <address>
        <city>Krugerson</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Dominican Republic</country>
    <country>Ecuador</country>
    <country>Honduras</country>
    <country>Panama</country>
    <country>South Africa</country>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 25, 2006</study_first_submitted>
  <study_first_submitted_qc>July 25, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 27, 2006</study_first_posted>
  <results_first_submitted>October 1, 2010</results_first_submitted>
  <results_first_submitted_qc>November 29, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 4, 2012</results_first_posted>
  <last_update_submitted>December 16, 2016</last_update_submitted>
  <last_update_submitted_qc>December 16, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Nail fungus</keyword>
  <keyword>Onychomycosis</keyword>
  <keyword>Itraconazole</keyword>
  <keyword>Toenail</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Onychomycosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Itraconazole</mesh_term>
    <mesh_term>Hydroxyitraconazole</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited from clinics in the US, Canada, South America, Ecuador, Dominican Republic, Panama, and Honduras.</recruitment_details>
      <pre_assignment_details>Subjects were screened prior to randomization and had to have a positive result from a mycological culture of their toe nail (ie, culture that was positive for dermatophytes). If the culture was negative, they were not randomized to receive treatment and were discontinued from the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Itraconazole Tablets</title>
          <description>Itraconazole 200 mg tablets. Subjects took one 200 mg tablet once per day after a full meal. The last dose was taken the day before the Week 12 visit.</description>
        </group>
        <group group_id="P2">
          <title>Itraconazole Capsules</title>
          <description>Itraconazole 100 mg capsules</description>
        </group>
        <group group_id="P3">
          <title>Placebo Tablets</title>
          <description>Tablets that were the same as the Itraconazole tables except that they did not contain the active drug (Itraconazole).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="593"/>
                <participants group_id="P2" count="590"/>
                <participants group_id="P3" count="198"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="517"/>
                <participants group_id="P2" count="496"/>
                <participants group_id="P3" count="156"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="76"/>
                <participants group_id="P2" count="94"/>
                <participants group_id="P3" count="42"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Non compliance</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="34"/>
                <participants group_id="P3" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="31"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Miscellaneous reasons</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Itraconazole Tablets</title>
          <description>Itraconazole 200 mg tablets. Subjects took one 200 mg tablet once per day after a full meal. The last dose was taken the day before the Week 12 visit.</description>
        </group>
        <group group_id="B2">
          <title>Itraconazole Capsules</title>
          <description>Itraconazole 100 mg capsules</description>
        </group>
        <group group_id="B3">
          <title>Placebo Tablets</title>
          <description>Tablets that were the same as the Itraconazole tables except that they did not contain the active drug (Itraconazole).</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="593"/>
            <count group_id="B2" value="590"/>
            <count group_id="B3" value="198"/>
            <count group_id="B4" value="1381"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47.1" spread="11.86"/>
                    <measurement group_id="B2" value="47" spread="12.67"/>
                    <measurement group_id="B3" value="49.2" spread="11.12"/>
                    <measurement group_id="B4" value="47.4" spread="12.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="441"/>
                    <measurement group_id="B2" value="440"/>
                    <measurement group_id="B3" value="153"/>
                    <measurement group_id="B4" value="1034"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="152"/>
                    <measurement group_id="B2" value="150"/>
                    <measurement group_id="B3" value="45"/>
                    <measurement group_id="B4" value="347"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <description>Subjects were permitted to select all choices from the list that apply to them with regard to race; ie, multiracial subjects would have checked more than one box and it would have been reported as such. Therefore the total number of subjects reported for race is greater than the number enrolled.</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="512"/>
                    <measurement group_id="B2" value="493"/>
                    <measurement group_id="B3" value="169"/>
                    <measurement group_id="B4" value="1174"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <description>Participants were permitted to select all choices from the list that apply to them with regard to race; ie, multiracial participants would have checked more than one box and it would have been reported as such. Therefore the total number of participants reported for race is greater than the number enrolled.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Panama</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="527"/>
                    <measurement group_id="B2" value="523"/>
                    <measurement group_id="B3" value="176"/>
                    <measurement group_id="B4" value="1226"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ecuador</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Honduras</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dominican Republic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>South Africa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Clinical and Mycological Cure of Target Toenail</title>
        <description>This study was designed to evaluate the superiority of itraconazole tablets to placebo tablets.
Clinical Cure was defined as an IGA score of 0 for the target toenail; Mycological Cure was defined as a negative potassium hydroxide (KOH) exam and a negative culture for dermatophytes of the target toenail.</description>
        <time_frame>1 year</time_frame>
        <population>Intent to treat (ITT).</population>
        <group_list>
          <group group_id="O1">
            <title>Itraconazole Tablets</title>
            <description>Itraconazole 200mg tablets</description>
          </group>
          <group group_id="O2">
            <title>Placebo Tablets</title>
          </group>
        </group_list>
        <measure>
          <title>Clinical and Mycological Cure of Target Toenail</title>
          <description>This study was designed to evaluate the superiority of itraconazole tablets to placebo tablets.
Clinical Cure was defined as an IGA score of 0 for the target toenail; Mycological Cure was defined as a negative potassium hydroxide (KOH) exam and a negative culture for dermatophytes of the target toenail.</description>
          <population>Intent to treat (ITT).</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="593"/>
                <count group_id="O2" value="198"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.3"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>P-Value from a Cochran-Mantel-Haenszel test, . The superiority analysis was restricted to the itraconazole 200-mg tablets and placebo tablets dosing groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>This was stratified by analysis center.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Complete Cure - Itraconazole Tablets Compared to Itraconazole Capsules</title>
        <description>The primary efficacy endpoint was Compete Cure (consisting of a Clinical Cure and a Mycological Cure) at week 52. In this study, Clinical Cure was defined as an Investigator’s Global Assessment (IGA) score of 0 for the target toenail; Mycological Cure was defined as a negative potassium hydroxide (KOH) examination and a negative culture outcome for dermatophytes of the target toenail. The efficacy analyses were conducted to demonstrate the non-inferiority of 1 itraconazole 200-mg tablet to 2 itraconazole 100-mg capsule.</description>
        <time_frame>12 months</time_frame>
        <population>Intent to treat (ITT).</population>
        <group_list>
          <group group_id="O1">
            <title>Itraconazole Tablets</title>
            <description>Itraconazole 200 mg tablets. Subjects took one 200 mg tablet once per day after a full meal. The last dose was taken the day before the Week 12 visit.</description>
          </group>
          <group group_id="O2">
            <title>Itraconazole Capsules</title>
            <description>Itraconazole 100 mg capsules</description>
          </group>
          <group group_id="O3">
            <title>Placebo Tablets</title>
            <description>Tablets that were the same as the Itraconazole tables except that they did not contain the active drug (Itraconazole).</description>
          </group>
        </group_list>
        <measure>
          <title>Complete Cure - Itraconazole Tablets Compared to Itraconazole Capsules</title>
          <description>The primary efficacy endpoint was Compete Cure (consisting of a Clinical Cure and a Mycological Cure) at week 52. In this study, Clinical Cure was defined as an Investigator’s Global Assessment (IGA) score of 0 for the target toenail; Mycological Cure was defined as a negative potassium hydroxide (KOH) examination and a negative culture outcome for dermatophytes of the target toenail. The efficacy analyses were conducted to demonstrate the non-inferiority of 1 itraconazole 200-mg tablet to 2 itraconazole 100-mg capsule.</description>
          <population>Intent to treat (ITT).</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="593"/>
                <count group_id="O2" value="590"/>
                <count group_id="O3" value="198"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.3"/>
                    <measurement group_id="O2" value="21.7"/>
                    <measurement group_id="O3" value="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison between the 2 itraconazole groups was based on lower bound of the 97.5% confidence interval for the difference. The non-inferiority analysis was restricted to the active dosing groups.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority was established if the lower limit of the one-sided, 97.5% CI in the observed difference between the proportions of subjects by study drug with Complete Cure at week 52 (itraconazole 200-mg tablets minus itraconazole 100-mg capsules) was greater than -10%. No p-value was calculated for this endpoint.</non_inferiority_desc>
            <param_type>Wald's CI</param_type>
            <param_value>0.56</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_lower_limit>-4.3</ci_lower_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Improvement of the Target Toenail</title>
        <description>Clinical Improvement consisted of a mycological cure and an Investigator's Global Assessment (IGA) score less than or equal to 1 at week 52.
The Investigator’s Global Assessment (IGA) assesses the overall severity of onychomycosis on the target toenail and takes into consideration, onycholysis, hyperkeratosis and percent nail involvement.
0 = Clinical Cure: No evidence of onychomycosis.
1 = Clinical Improvement: Minimal evidence of onychomycosis. 2 = Mild: ≤25% dystrophy and/or onycholysis. 3 = Moderate: ≤50% dystrophy with onycholysis. 4 = Severe: &gt;50% dystrophy with onycholysis.</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Itraconazole Tablets</title>
            <description>Itraconazole 200mg tablets</description>
          </group>
          <group group_id="O2">
            <title>Itraconazole Capsules</title>
            <description>Itraconazole 100mg capsules</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Improvement of the Target Toenail</title>
          <description>Clinical Improvement consisted of a mycological cure and an Investigator's Global Assessment (IGA) score less than or equal to 1 at week 52.
The Investigator’s Global Assessment (IGA) assesses the overall severity of onychomycosis on the target toenail and takes into consideration, onycholysis, hyperkeratosis and percent nail involvement.
0 = Clinical Cure: No evidence of onychomycosis.
1 = Clinical Improvement: Minimal evidence of onychomycosis. 2 = Mild: ≤25% dystrophy and/or onycholysis. 3 = Moderate: ≤50% dystrophy with onycholysis. 4 = Severe: &gt;50% dystrophy with onycholysis.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="593"/>
                <count group_id="O2" value="590"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.7"/>
                    <measurement group_id="O2" value="29.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The test for demonstrating non-inferiority was based on a margin of 10%. Thus, non-inferiority was established if the lower limit of the one-sided, 97.5% CI in the observed difference between the proportions of subjects by study drug with Complete Cure at week 52 (itraconazole 200-mg tablets minus itraconazole 100-mg capsules) was greater than -10%. The non-inferiority analysis was restricted to the active dosing groups.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The assumption was that the Complete Cure rate at week 52 was 35% for the active dosing groups, a sample size of 552 ITT subjects per active group would have had a 93% power for testing the proportion of subjects with Complete Cure. These computations assumed a non inferiority margin of 10% and a one-sided significance level of 0.025. Power computations were performed using nQuery Advisor, Version 5.0.</non_inferiority_desc>
            <p_value>&lt; 0.001</p_value>
            <method>Wald's CI</method>
            <method_desc>The statistical analysis used Wald’s CI with Yates’ continuity correction.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>10</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_lower_limit>-1.1</ci_lower_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Improvement Compared to Placebo</title>
        <description>Clinical Improvement consisted of a mycological cure and an Investigator's Global Assessment (IGA) score less than or equal to 1 at week 52.
The Investigator's Global Assessment(IGA)assesses the overall severity of onychomycosis on the target toenail and takes into consideration, onycholysis, hyperkeratosis and percent nail involvement.
0 = Clinical Cure: No evidence of onychomycosis.
1 = Clinical Improvement: Minimal evidence of onychomycosis. 2 = Mild: ≤25% dystrophy and/or onycholysis. 3 = Moderate: ≤50% dystrophy with onycholysis. 4 = Severe: &gt;50% dystrophy with onycholysis.</description>
        <time_frame>12 months</time_frame>
        <population>Intent to treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>Itraconazole Tablets</title>
            <description>Itraconazole 200mg tablets</description>
          </group>
          <group group_id="O2">
            <title>Placebo Tablets</title>
          </group>
        </group_list>
        <measure>
          <title>Clinical Improvement Compared to Placebo</title>
          <description>Clinical Improvement consisted of a mycological cure and an Investigator's Global Assessment (IGA) score less than or equal to 1 at week 52.
The Investigator's Global Assessment(IGA)assesses the overall severity of onychomycosis on the target toenail and takes into consideration, onycholysis, hyperkeratosis and percent nail involvement.
0 = Clinical Cure: No evidence of onychomycosis.
1 = Clinical Improvement: Minimal evidence of onychomycosis. 2 = Mild: ≤25% dystrophy and/or onycholysis. 3 = Moderate: ≤50% dystrophy with onycholysis. 4 = Severe: &gt;50% dystrophy with onycholysis.</description>
          <population>Intent to treat (ITT)</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="593"/>
                <count group_id="O2" value="198"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.7"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The superiority analysis was restricted to the itraconazole 200-mg tablets and placebo tablets dosing groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>This was stratified by analysis center.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>AEs and SAES are reported for the 12 week treatment period. SAEs are reported for both the treatment &amp; follow-up periods in the Additional Description section.</time_frame>
      <desc>During the follow-up period, 20 subjects (10, 9, and 1 in the itraconazole 200-mg tablet, itraconazole 100-mg capsule, and placebo tablet dosing groups, respectively) reported SAEs. Because 1 subject experienced a SAE in both periods of the study, 25 individual subjects experienced SAEs during the course of the trial.</desc>
      <group_list>
        <group group_id="E1">
          <title>Itraconazole Tablets - Treatment Period</title>
          <description>Itraconazole 200mg tablets Adverse events that occurred during the Treatment Period are reported here.</description>
        </group>
        <group group_id="E2">
          <title>Itraconazole Capsules</title>
          <description>Itraconazole 100mg capsules Adverse events that occurred during the Treatment Period are reported here.</description>
        </group>
        <group group_id="E3">
          <title>Placebo Tablets</title>
          <description>Adverse events that occurred during the Treatment Period are reported here.</description>
        </group>
        <group group_id="E4">
          <title>Itraconazole Tablets - Follow-up Period</title>
          <description>Adverse events that occurred during the follow-up (no treatment) period are reported here.</description>
        </group>
        <group group_id="E5">
          <title>Itraconazole Capsules - Follow-up Period</title>
          <description>Adverse events that occurred during the follow-up (no treatment) period are reported here.</description>
        </group>
        <group group_id="E6">
          <title>Placebo Tablets - Follow-up Period</title>
          <description>Adverse events that occurred during the follow-up (no treatment) period are reported here.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (9.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="582"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="581"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="535"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="515"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="582"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="581"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="535"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="515"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina Unstable</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="582"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="581"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="535"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="582"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="581"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="535"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="582"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="581"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="535"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="515"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="582"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="581"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="535"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Myocardial ischemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="582"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="581"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="535"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="515"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastric ulcer haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="582"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="581"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="535"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="515"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="582"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="581"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="535"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="582"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="581"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="535"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="515"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="582"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="581"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="535"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="515"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="582"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="581"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="535"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Jaw Fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="582"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="581"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="535"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="515"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Neck Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="582"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="581"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="535"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Brain cancer metastatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="582"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="581"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="535"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Glioblatoma multiforme</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="582"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="581"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="535"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="515"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Laryngeal cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="582"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="581"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="535"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="582"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="581"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="535"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Non-small cenll lung caner stage IV</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="582"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="581"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="535"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Prostate Cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="582"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="581"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="535"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Thyroid gland cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="582"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="581"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="535"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Uterine cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="582"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="581"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="535"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Carteroid artery aneurysm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="582"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="581"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="535"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="515"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="582"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="581"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="535"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="515"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus ureteric</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="582"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="581"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="535"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="515"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="582"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="581"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="191"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="535"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="515"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (9.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="582"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="581"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="191"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="535"/>
                <counts group_id="E5" subjects_affected="36" subjects_at_risk="515"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoacusis</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="582"/>
                <counts group_id="E2" events="16" subjects_affected="16" subjects_at_risk="581"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="191"/>
                <counts group_id="E4" events="19" subjects_affected="19" subjects_at_risk="535"/>
                <counts group_id="E5" events="36" subjects_affected="36" subjects_at_risk="515"/>
                <counts group_id="E6" events="8" subjects_affected="8" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

